Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1643-1652

  Saigusa, Susumu ^a   Inoue, Yasuhiro ^a   Tanaka, Koji ^a   Toiyama, Yuji ^a   Matsushita, Kohei ^a   Kawamura, Mikio ^a   Okugawa, Yoshinaga ^a   Hiro, Junic ^a   Uchida, Keiichi ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

CD44; Chemoradiotherapy; Disease recurrence; LGR5; Poor prognosis; Rectal cancer

Indexed keywords

FLUOROURACIL; HERMES ANTIGEN; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; PROTEIN; UFT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LOCALLY ADVANCED RECTUM CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIGENS, CD44; CHEMORADIOTHERAPY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; RECTAL NEOPLASMS; RECURRENCE; STROMAL CELLS;

EID: 84867777294     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1598     Document Type: Article

References (37)

1. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
2. Sebag-Montefiore D, Stephens RJ, Steele R, et al: Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373: 811-820, 2009.
3. Bosset JF, Collette L, Calais G, et al: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355: 1114-1123, 2006. (Pubitemid 44394918)
4. Guillem JG, Chessin DB, Cohen AM, et al: Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241: 829-838, 2005. (Pubitemid 40604929)
5. Barker N, van Es JH, Kuipers J, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007, 2007. (Pubitemid 350014593)
6. Becker L, Huang Q and Mashimo H: Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Sci World J 8: 1168-1176, 2008.
7. Haegebarth A and Clevers H: Wnt signaling, lgr5, and stem cells in the intestine and skin. Am J Pathol 174: 715-721, 2009.
8. Sato T, Vries RG, Snippert HJ, et al: Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459: 262-265, 2009.
9. Barker N, Ridgway RA, van Es JH, et al: Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-611, 2009.
10. Uchida H, Yamazaki K, Fukuma M, et al: Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 101: 1731-1737, 2010.
11. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45, 2003. (Pubitemid 36077255)
12. Nagano O and Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci 95: 930-935, 2004. (Pubitemid 40089583)
13. Reya T, Morrison SJ, Clarke MF, et al: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
14. Vermeulen L, Sprick MR, Kemper K, et al: Cancer stem cells - old concepts, new insights. Cell Death Differ 15: 947-958, 2008. (Pubitemid 351712600)
15. Thenappan A, Li Y, Shetty K, et al: New therapeutics targeting colon cancer stem cells. Curr Colorectal Cancer Rep 5: 209, 2009.
16. Marhaba R and Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231, 2004. (Pubitemid 40585308)
17. Subramaniam V, Vincent IR, Gardner H, et al: CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 83: 207-215, 2007. (Pubitemid 47320661)
18. Jothy S: CD44 and its partners in metastasis. Clin Exp Metastasis 20: 195-201, 2003.
19. Lopez JI, Camenisch TD, Stevens MV, et al: CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 65: 6755-6763, 2005. (Pubitemid 41060713)
20. Lakshman M, Subramaniam V, Rubenthiran U, et al: CD44 promotes resistance to apoptosis in human colon cancer cells. Exp Mol Pathol 77: 18-25, 2004. (Pubitemid 38822923)
21. Zeki SS, Graham TA and Wright NA: Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 8: 90-100, 2011.
22. Wielenga VJ, Smits R, Korinek V, et al: Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523, 1999. (Pubitemid 29094101)
23. Kim BM, Mao J, Taketo MM, et al: Phases of canonical Wnt signaling during the development of mouse intestinal epithelium. Gastroenterology 133: 529-538, 2007. (Pubitemid 47187338)
24. Yoshikawa R, Kusunoki M, Yanagi H, et al: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001. (Pubitemid 32174421)
25. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62: 679-694, 1989.
26. Viani GA, Stefano EJ, Soares FV, et al: Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and meta-regression. Int J Radiat Oncol Biol Phys 80: 985-991, 2011.
27. Rodel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696, 2005. (Pubitemid 46211512)
28. Ryan R, Gibbons D, Hyland JM, et al: Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47: 141-146, 2005. (Pubitemid 41113116)
29. Saigusa S, Tanaka K, Toiyama Y, et al: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 16: 3488-3498, 2009.
30. Bijwaard KE, Aguilera NS, Monczak Y, et al: Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47: 195-201, 2001. (Pubitemid 32142916)
31. Watanabe T: Chemoradiotherapy and adjuvant chemotherapy for rectal cancer. Int J Clin Oncol 13: 488-497, 2008.
32. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006. (Pubitemid 44949604)
33. Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005. (Pubitemid 40558990)
34. Kanwar SS, Yu Y, Nautiyal J, et al: The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 9: 212, 2010.
35. Takahashi H, Ishii H, Nishida N, et al: Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 18: 1166-1174, 2011.
36. Choi SH, Takahashi K, Eto H, et al: CD44s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer 85: 523-526, 2000. (Pubitemid 30075131)
37. Mulder JW, Wielenga VJ, Polak MM, et al: Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 36: 76-80, 1995.